Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 185 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
3. Cita con resumen
Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]
4.Tiene citas relacionadas Cita con resumen
Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med 2017;177:67-76. [Ref.ID 101344]
5. Cita con resumen
Anónimo. Hypertension artérielle essentielle chez un adulte: premiers traitements. Prescrire 2015;35:683-6. [Ref.ID 99722]
6.Tiene citas relacionadas Cita con resumen
Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Tonkin A, Webster R, Billot L, Bompoint S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A, for the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology 2015;22:920-30. [Ref.ID 99443]
7.Tiene citas relacionadas Cita con resumen
Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Paraq V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318. [Ref.ID 98026]
9. Cita con resumen
Anónimo. Tablet splitting. JAMA 2014;311:521. [Ref.ID 97095]
10.Tiene citas relacionadas
de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013;369:1960-2. [Ref.ID 96540]
11.Tiene citas relacionadas Cita con resumen
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903. [Ref.ID 96537]
12. Cita con resumen
Anónimo. Drug-induced liver injury. Australian Prescriber 2013;36:168-9. [Ref.ID 96320]
13.Tiene citas relacionadas Cita con resumen
Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Bompoint S, Billot L, Rodgers A, UMPIRE Collaborative Group. Effects of a fixed -dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918-29. [Ref.ID 96053]
14.Tiene citas relacionadas
Gaziano JM. Progress with the polypill?. JAMA 2013;310:910-1. [Ref.ID 96052]
15.Enlace a cita original Cita con resumen
Gao Y, O'Caoimh R, Healy L, Kerins DM, Eustace J, Guyatt G, Sammon D, Molloy DW. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013;3:22 de julio. [Ref.ID 95839]
16. Cita con resumen
Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. Pharmacoepidemiol Drug Saf 2012;21:1173-82. [Ref.ID 93988]
18.Tiene citas relacionadas Cita con resumen
Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-hispanic whites. Arch Intern Med 2012;172:1246-51. [Ref.ID 93758]
19. Cita con resumen
Anónimo. Candesartan. Fetal malformations. Australia. WHO Pharmaceuticals Newsletter 2012;4:4. [Ref.ID 93675]
20. Cita con resumen
Seleccionar todas
 
 1 a 20 de 185 siguiente >>